Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016, Article ID 5683097, 6 pages
http://dx.doi.org/10.1155/2016/5683097
Review Article

The Preclinical Research Progress of Stem Cells Therapy in Parkinson’s Disease

1Cell Therapy Laboratory, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei 050031, China
2Department of Immunology, Basic Medical College, Hebei Medical University, Shijiazhuang, Hebei 050017, China
3Department of Paediatrics, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei 050031, China
4Department of General Surgery, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei 050031, China
5Department of Neurology, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei 050031, China
6Department of Cardiac Surgery, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei 050031, China
7School of Nursing, Hebei Medical University, Shijiazhuang, Hebei, China
8Department of Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China

Received 14 August 2015; Accepted 21 April 2016

Academic Editor: Anelli Tiziana

Copyright © 2016 Jun Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. J. Kish, K. Shannak, and O. Hornykiewicz, “Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease: pathophysiologic and clinical implications,” The New England Journal of Medicine, vol. 318, no. 14, pp. 876–880, 1988. View at Publisher · View at Google Scholar
  2. D. J. Burn and R. A. Barker, “Mild cognitive impairment in Parkinson's disease: millstone or milestone?” Practical Neurology, vol. 13, no. 2, pp. 68–69, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. C. H. Williams-Gray, J. R. Evans, A. Goris et al., “The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort,” Brain, vol. 132, no. 11, pp. 2958–2969, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. J. A. Obeso, C. W. Olanow, and J. G. Nutt, “Levodopa motor complications in Parkinson's disease,” Trends in Neurosciences, vol. 23, supplement 1, pp. S2–S7, 2000. View at Publisher · View at Google Scholar
  5. A. E. Lang and A. M. Lozano, “Parkinson's disease,” The New England Journal of Medicine, vol. 339, no. 15, pp. 1044–1053, 1998. View at Publisher · View at Google Scholar · View at Scopus
  6. C. W. Olanow, M. B. Stern, and K. Sethi, “The scientific and clinical basis for the treatment of Parkinson disease (2009),” Neurology, vol. 72, no. 21, supplement 4, pp. S1–S136, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. O. Lindvall, Z. Kokaia, and A. Martinez-Serrano, “Stem cell therapy for human neurodegenerative disorders—how to make it work,” Nature Medicine, vol. 10, supplement, pp. S42–S50, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Dezawa, H. Kanno, M. Hoshino et al., “Specific induction of neuronal cells from bone marrow stromal cells and application for autologous transplantation,” The Journal of Clinical Investigation, vol. 113, no. 12, pp. 1701–1710, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Takagi, J. Takahashi, H. Saiki et al., “Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model,” The Journal of Clinical Investigation, vol. 115, no. 1, pp. 102–109, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. M.-S. Cho, D.-Y. Hwang, and D.-W. Kim, “Efficient derivation of functional dopaminergic neurons from human embryonic stem cells on a large scale,” Nature Protocols, vol. 3, no. 12, pp. 1888–1894, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Kirkeby, S. Grealish, D. A. Wolf et al., “Generation of regionally specified neural progenitors and functional neurons from human embryonic stem cells under defined conditions,” Cell Reports, vol. 1, no. 6, pp. 703–714, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Sundberg, H. Bogetofte, T. Lawson et al., “Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons,” Stem Cells, vol. 31, no. 8, pp. 1548–1562, 2013. View at Publisher · View at Google Scholar
  13. S. Park, K. S. Lee, Y. J. Lee et al., “Generation of dopaminergic neurons in vitro from human embryonic stem cells treated with neurotrophic factors,” Neuroscience Letters, vol. 359, no. 1-2, pp. 99–103, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Acquarone, T. M. de Melo, F. Meireles et al., “Mitomycin-treated undifferentiated embryonic stem cells as a safe and effective therapeutic strategy in a mouse model of Parkinson's disease,” Frontiers in Cellular Neuroscience, vol. 9, article 97, 2015. View at Publisher · View at Google Scholar
  15. S. Kriks, J.-W. Shim, J. Piao et al., “Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease,” Nature, vol. 480, no. 7378, pp. 547–551, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. J. A. Steinbeck and L. Studer, “Moving stem cells to the clinic: potential and limitations for brain repair,” Neuron, vol. 86, no. 1, pp. 187–206, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. J. A. Steinbeck, S. J. Choi, A. Mrejeru et al., “Optogentics enables functional analysis of human embryonic stem cell-derived grafts in a Parkinson's disease model,” Nature Biotechnology, vol. 33, no. 2, pp. 204–209, 2015. View at Google Scholar
  18. M. Zarrabi, S. H. Mousavi, H. Abroun et al., “Potential uses for cord blood mesenchymal stem cells,” Cell Journal, vol. 15, no. 4, pp. 274–281, 2014. View at Google Scholar
  19. F. Morandi, L. Raffaghello, G. Bianchi et al., “Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumor-associated antigens,” STEM CELLS, vol. 26, no. 5, pp. 1275–1287, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Woochul, W. S. Byeong, and C. H. Ki, “Mesenchymal stem cell survival in infarcted myocardium: adhesion and anti-death signals,” Stem Cells and Cancer Stem Cells, vol. 10, pp. 35–43, 2013. View at Google Scholar
  21. S. Lee, E. Choi, M.-J. Cha, and K.-C. Hwang, “Cell adhesion and long-term survival of transplanted mesenchymal stem cells: a prerequisite for cell therapy,” Oxidative Medicine and Cellular Longevity, vol. 2015, Article ID 632902, 9 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Y. Kim, H. B. Jeon, Y. S. Yang et al., “Application of human umbilical cord blood-derived mesenchymal stem cells in disease models,” World Journal of Stem Cells, vol. 2, no. 2, pp. 34–38, 2010. View at Google Scholar
  23. Y. S. Fu, Y. C. Cheng, M. A. Lin et al., “Conversion of human umbilical cord mesenchymal stem cells in Wharton's jelly to dopaminergic neurons in vitro: potential therapeutic application for Parkinsonism,” STEM CELLS, vol. 24, no. 1, pp. 115–124, 2006. View at Publisher · View at Google Scholar
  24. M. Yan, M. Sun, Y. Zhou et al., “Conversion of human umbilical cord mesenchymal stem cells in Wharton's jelly to dopamine neurons mediated by the Lmx1a and neurturin in vitro: potential therapeutic application for Parkinson's disease in a rhesus monkey model,” PLoS ONE, vol. 8, no. 5, Article ID e64000, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. T. T. Sibov, L. F. Pavon, L. A. Miyaki et al., “Umbilical cord mesenchymal stem cells labeled with multimodal iron oxide nanoparticles with fluorescent and magnetic properties: application for in vivo cell tracking,” International Journal of Nanomedicine, vol. 9, no. 1, pp. 337–350, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Jiaming and C. Niu, “Comparing neuroprotective effects of CDNF-expressing bone marrow derived mesenchymal stem cells via differing routes of administration utilizing an in vivo model of Parkinson's disease,” Neurological Sciences, vol. 36, no. 2, pp. 281–287, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. X. Yin, H. Xu, Y. Jiang et al., “The effect of lentivirus-mediated PSPN genetic engineering bone marrow mesenchymal stem cells on Parkinson's disease rat model,” PLoS ONE, vol. 9, no. 8, Article ID e105118, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. N. Xiong, H. Yang, L. Liu et al., “bFGF promotes the differentiation and effectiveness of human bone marrow mesenchymal stem cells in a rotenone model for Parkinson's disease,” Environmental Toxicology and Pharmacology, vol. 36, no. 2, pp. 411–422, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. L. Zhang, L. Liu, R. Thompson, and C. Chan, “CREB modulates calcium signaling in cAMP-induced bone marrow stromal cells (BMSCs),” Cell Calcium, vol. 56, no. 4, pp. 257–268, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. L. Mutlu, D. Hufnagel, and H. S. Taylor, “The endometrium as a source of mesenchymal stem cells for regenerative medicine,” Biology of Reproduction, vol. 92, no. 6, article 138, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. Z. T. Mobarakeh, J. Ai, F. Yazdani et al., “Human endometrial stem cells as a new source for programming to neural cells,” Cell Biology International Reports, vol. 19, no. 1, Article ID e00015, 2010. View at Publisher · View at Google Scholar
  32. E. F. Wolff, X.-B. Gao, K. V. Yao et al., “Endometrial stem cell transplantation restores dopamine production in a Parkinson's disease model,” Journal of Cellular and Molecular Medicine, vol. 15, no. 4, pp. 747–755, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. E. F. Wolff, L. Mutlu, E. E. Massasa, J. D. Elsworth, D. Eugene Redmond, and H. S. Taylor, “Endometrial stem cell transplantation in MPTP- exposed primates: an alternative cell source for treatment of Parkinson's disease,” Journal of Cellular and Molecular Medicine, vol. 19, no. 1, pp. 249–256, 2015. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Ernst, K. Alkass, S. Bernard et al., “Neurogenesis in the striatum of the adult human brain,” Cell, vol. 156, no. 5, pp. 1072–1083, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. S. J. Morrison, “Neuronal potential and lineage determination by neural stem cells,” Current Opinion in Cell Biology, vol. 13, no. 6, pp. 666–672, 2001. View at Publisher · View at Google Scholar · View at Scopus
  36. J. N. Le Grand, L. Gonzalez-Cano, M. A. Pavlou, and J. C. Schwamborn, “Neural stem cells in Parkinson's disease: a role for neurogenesis defects in onset and progression,” Cellular and Molecular Life Sciences, vol. 72, no. 4, pp. 773–797, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. E. Paldino, C. Cenciarelli, A. Giampaolo et al., “Induction of dopaminergic neurons from human Wharton's jelly mesenchymal stem cell by forskolin,” Journal of Cellular Physiology, vol. 229, no. 2, pp. 232–244, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. P. Casalbore, M. Budoni, L. Ricci-Vitiani et al., “Tumorigenic potential of olfactory bulb-derived human adult neural stem cells associates with activation of TERT and NOTCH1,” PLoS ONE, vol. 4, no. 2, Article ID e4434, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. H. E. S. Marei, S. Lashen, A. Farag et al., “Human olfactory bulb neural stem cells mitigate movement disorders in a rat model of Parkinson's disease,” Journal of Cellular Physiology, vol. 230, no. 7, pp. 1614–1629, 2015. View at Publisher · View at Google Scholar · View at Scopus
  40. X. Deng, Y. Liang, H. Lu et al., “Co-transplantation of GDNF-overexpressing neural stem cells and fetal dopaminergic neurons mitigates motorsymptoms in a rat model of Parkinson’s disease,” PLoS ONE, vol. 8, no. 12, Article ID e80880, 2013. View at Google Scholar
  41. D. R. Wakeman, D. E. Redmond Jr., H. B. Dodiya et al., “Human neural stem cells survive long term in the midbrain of dopamine-depleted monkeys after GDNF overexpression and project neurites toward an appropriate target,” Stem Cells Translational Medicine, vol. 3, no. 6, pp. 692–701, 2014. View at Publisher · View at Google Scholar · View at Scopus
  42. K. B. Bjugstad, Y. D. Teng, D. E. Redmond Jr. et al., “Human nerual stem cells migrate along the nigrostriatal pathway in a primate model of Parkinson's disease,” Experimental Neurology, vol. 211, no. 2, pp. 362–369, 2008. View at Google Scholar
  43. J. Harding, R. M. Roberts, and O. Mirochnitchenko, “Large animal models for stem cell therapy,” Stem Cell Research & Therapy, vol. 4, no. 2, p. 23, 2013. View at Publisher · View at Google Scholar
  44. Z. H. Ren, J. Y. Wang, C. L. Zou, Y. Guan, and Y. A. Zhang, “Labeling of cynomolgus monkey bone marrow-derived mesenchymal stem cells for cell tracking by multimodality imaging,” Science China Life Sciences, vol. 54, no. 11, pp. 981–987, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. B. Addicott, M. Willman, J. Rodriguez et al., “Mesenchymal stem cell labeling and in vitro MR characterization at 1.5 T of new SPIO contrast agent: Molday ION Rhodamine-B,” Contrast Media & Molecular Imaging, vol. 6, no. 1, pp. 7–18, 2011. View at Publisher · View at Google Scholar
  46. B.-N. Park, J.-H. Kim, K. Lee, S. H. Park, and Y.-S. An, “Improved dopamine transporter binding activity after bone marrow mesenchymal stem cell transplantation in a rat model of Parkinson’s disease: small animal positron emission tomography study with F-18 FP-CIT,” European Radiology, vol. 25, no. 5, pp. 1487–1496, 2015. View at Publisher · View at Google Scholar · View at Scopus